SAVR 2.0 cm2
8.6 mm Hg
SAVR 11.2 mm Hg
As demonstrated by all-cause mortality or disabling stroke, noninferior to SAVR at 24 months1
2-year Bayesian Analysis
n = 1,468
EvolutTM TAVI showed lower mortality, fewer disabling strokes, and fewer heart failure rehospitalisations compared to SAVR2
EVOLUTTM TAVI SUPERIOR TO SAVR
in self-reported KCCQ measures at 30 days1
58% SHORTER HOSPITAL STAY
with TAVI procedures vs. SAVR procedures2
LOWER RATES OF HEART FAILURE REHOSPITALISATION
with EvolutTM TAVI vs. SAVR at one year2
1. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. May 2, 2019;380(18):1706-1715.
2. Reardon MJ. The Evolut Low Risk Trial. Presented at ACC 2019; New Orleans, LA.
3. Herrmann HC, Daneshvar SA, Fonarow GC, et al. Prosthesis-Patient Mismatch in 62,125 Patients Following Transcatheter Aortic Valve Replacement: From the STS/ACC TVT Registry. J Am Coll Cardiol. Published online September 18, 2018.
*Severe PPM is associated with increased mortality and HF rehospitalizations at 1 year.